<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-15T13:51:48Z</responseDate>
  <request identifier="oai:figshare.com:article/34047376" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34047376</identifier>
        <datestamp>2026-10-01T17:22:57Z</datestamp>
        <setSpec>category_8</setSpec>
        <setSpec>category_12</setSpec>
        <setSpec>category_24</setSpec>
        <setSpec>category_272</setSpec>
        <setSpec>category_39</setSpec>
        <setSpec>category_46</setSpec>
        <setSpec>category_734</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>category_134</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_10_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Species tropism of bat and mammalian ACE with SARS-CoV-2 variants.&lt;/p&gt;</dc:title>
          <dc:creator>Nazia Thakur (9904162)</dc:creator>
          <dc:creator>Joseph Newman (5638340)</dc:creator>
          <dc:creator>Dongchun Ni (15188356)</dc:creator>
          <dc:creator>Jeffrey Seow (9415776)</dc:creator>
          <dc:creator>Abigail L. Hay (25157576)</dc:creator>
          <dc:creator>Yeonjae Lee (12256119)</dc:creator>
          <dc:creator>Ayush Upadhyay (25157573)</dc:creator>
          <dc:creator>Babatunde E. Ekundayo (25157578)</dc:creator>
          <dc:creator>John A. Hammond (7431785)</dc:creator>
          <dc:creator>Thomas P. Peacock (6536120)</dc:creator>
          <dc:creator>Kelvin Lau (1847764)</dc:creator>
          <dc:creator>Katie J. Doores (346210)</dc:creator>
          <dc:creator>Dalan Bailey (193037)</dc:creator>
          <dc:subject>Microbiology</dc:subject>
          <dc:subject>Cell Biology</dc:subject>
          <dc:subject>Evolutionary Biology</dc:subject>
          <dc:subject>Environmental Sciences not elsewhere classified</dc:subject>
          <dc:subject>Ecology</dc:subject>
          <dc:subject>Immunology</dc:subject>
          <dc:subject>Biological Sciences not elsewhere classified</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>Virology</dc:subject>
          <dc:subject>multiple bat coronaviruses</dc:subject>
          <dc:subject>g ., rc</dc:subject>
          <dc:subject>g ., civet</dc:subject>
          <dc:subject>clade 1 viruses</dc:subject>
          <dc:subject>restricted ace2 usage</dc:subject>
          <dc:subject>mammalian ace2 proteins</dc:subject>
          <dc:subject>g ., rhgb07</dc:subject>
          <dc:subject>using monoclonal antibodies</dc:subject>
          <dc:subject>clade 1 sarbecoviruses</dc:subject>
          <dc:subject>div &gt;&lt; p</dc:subject>
          <dc:subject>determined host range</dc:subject>
          <dc:subject>converting enzyme 2</dc:subject>
          <dc:subject>2 convalescent individuals</dc:subject>
          <dc:subject>ace2 ), via</dc:subject>
          <dc:subject>using binding assays</dc:subject>
          <dc:subject>antigenicity using sera</dc:subject>
          <dc:subject>related bat sarbecoviruses</dc:subject>
          <dc:subject>using sarbecoviruses</dc:subject>
          <dc:subject>host range</dc:subject>
          <dc:subject>clade 3</dc:subject>
          <dc:subject>pangolin ),</dc:subject>
          <dc:subject>neutralising antibodies</dc:subject>
          <dc:subject>entry assays</dc:subject>
          <dc:subject>binding domain</dc:subject>
          <dc:subject>sarbecoviruses interact</dc:subject>
          <dc:subject>sarbecoviruses exhibited</dc:subject>
          <dc:subject>rodent ace2</dc:subject>
          <dc:subject>like rhgb07</dc:subject>
          <dc:subject>generalist ace2</dc:subject>
          <dc:subject>related antigenicity</dc:subject>
          <dc:subject>zoonotic potential</dc:subject>
          <dc:subject>vitally important</dc:subject>
          <dc:subject>still evidence</dc:subject>
          <dc:subject>specialist &lt;/</dc:subject>
          <dc:subject>shifting pattern</dc:subject>
          <dc:subject>robust evidence</dc:subject>
          <dc:subject>research indicates</dc:subject>
          <dc:subject>racoon dog</dc:subject>
          <dc:subject>novel structure</dc:subject>
          <dc:subject>largely maintained</dc:subject>
          <dc:subject>including human</dc:subject>
          <dc:subject>immunodominant target</dc:subject>
          <dc:subject>human primate</dc:subject>
          <dc:subject>generalist phenotypes</dc:subject>
          <dc:subject>generalist &lt;/</dc:subject>
          <dc:subject>especially omicron</dc:subject>
          <dc:subject>entry phenotypes</dc:subject>
          <dc:subject>diverse panel</dc:subject>
          <dc:subject>continued evolution</dc:subject>
          <dc:subject>breakthrough infections</dc:subject>
          <dc:description>&lt;p&gt;&lt;b&gt;(A)&lt;/b&gt; Schematic of the emergence of SARS-CoV-2 variants depicting the divergence of the B lineage variants, including those variants of concern that grew to global dominance (B.1, Alpha, Beta, Delta, Omicron [black lines]), and the Omicron subvariants [red lines], some of which emerged via recombination events (dotted lines). Heatmap showing the bat and mammalian ACE2 usage of SARS-CoV-2 variants with &lt;b&gt;(B)&lt;/b&gt; the B.1, Alpha, Beta, Delta and BA.1 variants, or &lt;b&gt;(E)&lt;/b&gt; BA.2 and its subvariants BA.4/5, XBB, XBB1.5, BA.2.86. Data are shown as the mean fold change in pseudotype entry (RLU) of 3 separate experiments, relative to human ACE2. &lt;b&gt;(C)&lt;/b&gt; Structure of SARS-CoV-2 BA.1 (PDB 7XO7) with mutations listed compared to B.1. Zoomed images of the Spike protein for B.1 (PDB 6M0J) and BA.1 (PDB 7WBP), highlighting key residues at positions 417, 484, 493 and 501 and the resultant interactions with human ACE2. &lt;b&gt;(D)&lt;/b&gt; Specific amino acids within the B.1 RBD were mutagenised to make the RBD more BA.1-like (K417N, E484A, Q493R or N501Y) (top panel), or within BA.1 RBD to make the RBD more B.1-like (N417K, A484E, R493Q or Y501N) (bottom panel), either by themselves or in combination. Entry of these mutants was tested with &lt;i&gt;Rh. cornutus, Rh. pusillus&lt;/i&gt;, &lt;i&gt;Rh. ferrumequinum&lt;/i&gt;, and &lt;b&gt;&lt;i&gt;L.&lt;/i&gt;&lt;/b&gt; &lt;i&gt;Lyra&lt;/i&gt; ACE2s. Data is shown as log fold-change in pseudotype entry, with green bars indicating an increase in virus entry and blue bars a decrease in entry, relative to B.1 (top panel) or BA.1 (bottom panel), highlighted also in &lt;a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003944#pbio.3003944.g004" target="_blank"&gt;Fig 4B&lt;/a&gt;. The data underlying this Figure can be found in &lt;a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003944#pbio.3003944.s017" target="_blank"&gt;S1 Data&lt;/a&gt;.&lt;/p&gt;</dc:description>
          <dc:date>2026-10-01T17:40:07Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.pbio.3003944.g004</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_Species_tropism_of_bat_and_mammalian_ACE_with_SARS-CoV-2_variants_p_/34047376</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
